




PHARMACEUTICAL 2018

Pfenex Inc.
Rank 125 of 342





PHARMACEUTICAL 2018

Pfenex Inc.
Rank 125 of 342

The relative strengths and weaknesses of Pfenex Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Pfenex Inc. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 31% points. The greatest weakness of Pfenex Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 146%, being 100% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	61,513
Cost of Goods Sold	5,156
Intangible Assets	10,348
Liabilities, Current	18,467
Liabilities, Non-Current	0
Other Assets	133
Other Compr. Net Income	0
Other Expenses	-172
Other Liabilities	3,161
Other Net Income	119
Other Revenues	28,780
Property and Equipment	7,397
Research and Development	31,925
Selling, General and Administrative Expense	17,674

Output Variable	Value in 1000 USD
Assets	79,391
Liabilities	21,628
Expenses	54,583
Revenues	28,780
Stockholders Equity	57,763
Net Income	-25,684
Comprehensive Net Income	-25,684
Economic Capital Ratio	146%